Navigation Links
Mass Biologic Labs/UMass Med School and Medarex license C. difficile monoclonal antibody to Merck
Date:4/21/2009

WHITEHOUSE STATION N.J., PRINCETON, N.J. and JAMAICA PLAIN, Mass., April 21, 2009 Merck & Co., Inc., (through an affiliate), Medarex, Inc. (NASDAQ: MEDX) and Massachusetts Biologic Laboratories (MBL) of the University of Massachusetts Medical School (UMMS) today announced that they have signed an exclusive worldwide license agreement for CDA-1 and CDB-1 (also known as MDX-066/MDX-1388 and MBL-CDA1/MBL-CDB1), an investigational fully human monoclonal antibody combination developed to target and neutralize Clostridium difficile toxins A and B, for the treatment of C. difficile infection (CDI). CDA-1 and CDB-1 were co-developed by Medarex and MBL.

Under the terms of the agreement, Merck gains worldwide rights to develop and commercialize CDA-1 and CDB-1. Medarex and MBL will receive an upfront payment of $60 million and are potentially eligible to receive additional cash payments up to $165 million upon achievement of certain milestones associated with the development and approval of a drug candidate covered by this agreement. Upon commercialization, Medarex and MBL will also be eligible to receive double-digit royalties on product sales and milestones if certain sales targets are met. In accordance with the co-development agreement between Medarex and MBL, all payments will be divided equally.

The incidence of C. difficile infection (CDI) in the U.S. is rapidly increasing, with rates doubling from 2000 to 2005. The Centers for Disease Control and Prevention has projected that there will be as many as 750,000 cases of CDI per year by 2010 .

"C. difficile infection is the primary cause of infectious diarrhea in hospitalized elderly patients in developed countries," said Tony Ford-Hutchinson, Ph.D., senior vice president and franchise head, Infectious Diseases and Vaccines, Merck Research Laboratories. "This agreement underscores Merck's ongoing commitment to infectious disease and our strategy of licens
'/>"/>

Contact: Mark Shelton
mark.shelton@umassmed.edu
508-856-2000
University of Massachusetts Medical School
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Keck Foundation funds study of biological interactions with nanomaterials
2. New insight into the mechanisms of voltage sensing and transduction in biological processes
3. Biological warfare: What do you need to know?
4. A mechanism to explain biological cross-talk between 24-hour body cycle and metabolism
5. Story ideas from the Journal of Biological Chemistry
6. Emerging field of neuroecology is showcased in December issue of the Biological Bulletin
7. Story ideas from the Journal of Biological Chemistry
8. Systems biologist finds novel solutions to fundamental biological problems
9. MIT applies engineering approach to studying biological pathways
10. Lensless camera uses X-rays to view nanoscale materials and biological specimens
11. Systems biology approach identifies nutrient regulation of biological clock in plants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a ... its PerformTek biometric technology to industry leaders such as ... accurate, clinically validated, biometric wearable products. These products will ... in Las Vegas . ... is accurate, flexible and robust – with the clinical ...
(Date:12/15/2014)... 2014 Research and Markets ( ... "Global Facial Recognition Market 2015-2019" report ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is a ... recognition system measures the overall facial feature of ... and the distance between eyes. Facial recognition is ...
(Date:12/11/2014)...  That blood pressure plays a role in human health ... medical term for high blood pressure – was first described ... cuff that,s used in measuring blood pressure was invented in ... about hypertension, its triggers and its effects. In fact, recent ... the best ways to treat it. For example, ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... The sweetgum tree grows widely throughout the country and is ... "gumballs." Now, this spiny fruit may become an important source ... bird flu ?a drug that is currently in short supply ... of the sweetgum fruit contain significant amounts of shikimic acid, ...
... A pain–killing medication appears to halt the production of ... of breast cancer, a new study using tissue cultures ... experiments on breast cancer cells, scientists found that derivatives ... implicated in estrogen-dependent breast cancer. This form of breast ...
... to show that molecular variation in one gene may ... habitat. Research Professor Ilkka Hanski, University of Helsinki, and ... the population growth of the Glanville fritillary butterfly (Melitaea ... phosphoglucose isomerase (Pgi) enzyme. The result challenges previous views ...
Cached Biology News:Sweetgum tree could help lessen shortage of bird flu drug 2Pain killer fights breast cancer by targeting key enzyme 2Pain killer fights breast cancer by targeting key enzyme 3New discovery: Molecular variation in one gene affects the growth of natural populations 2
(Date:12/19/2014)... MA (PRWEB) December 18, 2014 iLab ... announced the appointment of Siri Bryant as the new ... new Director of Core Implementations. These two new leadership ... outstanding customer service by ensuring that iLab continues to ... “In the last four years, iLab has been deployed ...
(Date:12/19/2014)... BURLINGTON, Mass. , Dec. 18, 2014  Decision ... dental biomaterial market will grow moderately through ... implant procedures and growing awareness of dental biomaterials all ... underdeveloped markets such as China ... incomes will bring dental procedures within reach for a ...
(Date:12/17/2014)... (PRWEB) December 16, 2014 The ... since 2013, which is why IBISWorld updated its original ... continues to benefit from an intensified focus on environmental ... for new emission standards for power plants and a ... According to IBISWorld Industry Analyst Sarah Kahn, “a range ...
(Date:12/17/2014)... N.J. (PRWEB) December 17, 2014 ... (Euronext: IPN; ADR: IPSEY), today announced ... (referred to as Somatuline®) was approved by the ... treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult ... advanced or metastatic disease to improve progression-free survival ...
Breaking Biology Technology:iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
... Sail graduate Darren Lynn Bousman, acclaimed Director of the ... its Full Sail Live facility on Monday, November 17, ... Repo! The Genetic Opera. The screening was followed by ... the university, and also featured actor and co-writer Terrance ...
... biotech firm and Laborium Biopharma, a subsidiary of Validapro Biosciences Inc. ... protein bioprocess production and scale-up. , ... Laval, Quebec ... firm and Laborium Biopharma, a subsidiary of Validapro Biosciences Inc. have ...
... ... St. Andrews by-the-Sea, ... https://www.atlanticabioenergy.com/ , NOTE TO EDITORS: Photo, video ... /PRNewswire/ - The global forestry industry is rapidly changing and it is incumbent on all stakeholders ...
Cached Biology Technology:Full Sail University Welcomed Back to Campus Graduate and Acclaimed Horror Director, Darren Lynn Bousman 2Full Sail University Welcomed Back to Campus Graduate and Acclaimed Horror Director, Darren Lynn Bousman 3Med Discovery and Laborium Biopharma Sign a Bioprocess Development Partnership Agreement 2Media Advisory - Atlantica BioEnergy Task Force Leaders' Roundtable 2
Immunogen: Synthetic peptide: N(171) H G F L S A D Q QL I K(183) Storage: -20 C, Avoid Freeze/Thaw Cycles...
The pCDF Expression System 1 plus Competent Cells contains 10 µg of pET-45b(+) DNA. pET-45b carries an N-terminal His•Tag ® coding sequence that is cleavable with enterokinase as well...
HIV-1 TAT (vN-21)...
Request Info...
Biology Products: